Resources from the same session
LBA47 - Activity of OSE-2101 in HLA-A2+ non-small cell lung cancer (NSCLC) patients after failure to immune checkpoint inhibitors (IO): Final results of phase III Atalante-1 randomised trial
Presenter: Benjamin Besse
Session: Proffered Paper session - NSCLC, metastatic 2
Resources:
Abstract
Slides
Webcast
1281O - Atezolizumab (atezo) vs platinum-based chemo in blood-based tumour mutational burden-positive (bTMB+) patients (pts) with first-line (1L) advanced/metastatic (m)NSCLC: Results of the Blood First Assay Screening Trial (BFAST) phase III cohort C
Presenter: Rafal Dziadziuszko
Session: Proffered Paper session - NSCLC, metastatic 2
Resources:
Abstract
Slides
Webcast
LBA48 - DUBLIN-3 (BPI-2358-103): A global phase (Ph) III trial with the plinabulin/docetaxel (Plin/Doc) combination vs. Doc in 2nd/3rd Line NSCLC patients (pts) with EGFR-wild type (wt) progressing on a prior platinum-based regimen
Presenter: Trevor Feinstein
Session: Proffered Paper session - NSCLC, metastatic 2
Resources:
Abstract
Slides
Webcast
1191O - MRTX-500: Phase II trial of sitravatinib (sitra) + nivolumab (nivo) in patients (pts) with non-squamous (NSQ) non-small cell lung cancer (NSCLC) progressing on or after prior checkpoint inhibitor (CPI) therapy
Presenter: Ticiana Leal
Session: Proffered Paper session - NSCLC, metastatic 2
Resources:
Abstract
Slides
Webcast
Q&A and live discussion
Presenter: Lyudmila Bazhenova
Session: Proffered Paper session - NSCLC, metastatic 2
Resources:
Slides
Webcast
Invited Discussant LBA48 & 1191O
Presenter: Maurice Pérol
Session: Proffered Paper session - NSCLC, metastatic 2
Resources:
Slides
Webcast
Invited Discussant LBA47 and 1281O
Presenter: Lyudmila Bazhenova
Session: Proffered Paper session - NSCLC, metastatic 2
Resources:
Slides
Webcast